|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| REVENUES | |||||
| Revenue | |||||
| Sale of medical devices | |||||
| Revenue | |||||
| Tax and surcharges | |||||
| Net Revenues | |||||
| Cost of revenue | |||||
| Gross Profit | |||||
| OPERATING EXPENSE | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Impairment of goodwill and intangible assets | |||||
| Total Operating Expenses | |||||
| LOSS FROM CONTINUING OPERATIONS | |||||
| OTHER (EXPENSE) INCOME | |||||
| Other income | |||||
| Other expense | |||||
| Exchange gain (loss) | |||||
| Total Other (Expense) Income, net | |||||
| LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | |||||
| (BENEFIT) PROVISON FOR INCOME TAXES | |||||
| NET LOSS FROM CONTINUING OPERATIONS | |||||
| Net loss from discontinued operations, net of income taxes | |||||
| Loss from disposal of discontinued operations, net of income taxes | |||||
| Total loss from discontinued operations | |||||
| NET LOSS | |||||
| Foreign currency translation adjustment | |||||
| COMPREHENSIVE LOSS | |||||
| Less: comprehensive income (loss) attributable to non-controlling interest | |||||
| Less: comprehensive loss attributable to non-controlling interest | |||||
| COMPREHENSIVE LOSS ATTRIBUTABLE TO AKSO’S SHAREHOLDERS | |||||
| Continuing operations | |||||
| Basic (in Dollars per share) | |||||
| Diluted (in Dollars per share) | |||||
| Net (loss) per share | |||||
| Basic (in Dollars per share) | |||||
| Diluted (in Dollars per share) | |||||
| Weighted average shares | |||||
| Basic (in Shares) | |||||
| Diluted (in Shares) | |||||
| Less: net loss attributable to non-controlling interest | |||||
| NET LOSS ATTRIBUTABLE TO AKSO’S SHAREHOLDERS | |||||
Loading...